Aeglea Bio Therapeutics Alpha and Beta Analysis
| AGLEDelisted Stock | USD 0.59 0.01 1.72% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Aeglea Bio Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Aeglea Bio over a specified time horizon. Remember, high Aeglea Bio's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Aeglea Bio's market risk premium analysis include:
Beta (2.05) | Alpha 5.04 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Aeglea |
Aeglea Bio Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Aeglea Bio market risk premium is the additional return an investor will receive from holding Aeglea Bio long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Aeglea Bio. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Aeglea Bio's performance over market.| α | 5.04 | β | -2.05 |
Aeglea Bio Fundamentals Vs Peers
Comparing Aeglea Bio's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Aeglea Bio's direct or indirect competition across all of the common fundamentals between Aeglea Bio and the related equities. This way, we can detect undervalued stocks with similar characteristics as Aeglea Bio or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Aeglea Bio's fundamental indicators could also be used in its relative valuation, which is a method of valuing Aeglea Bio by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Aeglea Bio to competition |
| Fundamentals | Aeglea Bio | Peer Average |
| Return On Equity | -2.81 | -0.31 |
| Return On Asset | -0.42 | -0.14 |
| Operating Margin | (94.85) % | (5.51) % |
| Current Valuation | 228.21 M | 16.62 B |
| Shares Outstanding | 4.05 M | 571.82 M |
| Shares Owned By Insiders | 2.40 % | 10.09 % |
| Shares Owned By Institutions | 97.60 % | 39.21 % |
Aeglea Bio Opportunities
Aeglea Bio Return and Market Media
The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
1 | Aeglea Bio Therapeutics earnings beat, revenue topped estimates | 05/11/2023 |
2 | Take the Zacks Approach to Beat the Market Shopify, Oracle, Uber in Focus - Yahoo Finance | 06/26/2023 |
3 | Novo Nordisk turns RNA attention to cardio disease in new pact - FierceBiotech | 07/17/2023 |
About Aeglea Bio Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Aeglea or other delisted stocks. Alpha measures the amount that position in Aeglea Bio Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Aeglea Bio Upcoming Company Events
As portrayed in its financial statements, the presentation of Aeglea Bio's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Aeglea Bio's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Aeglea Bio's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Aeglea Bio. Please utilize our Beneish M Score to check the likelihood of Aeglea Bio's management manipulating its earnings.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Aeglea Bio
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in Aeglea Stock
If you are still planning to invest in Aeglea Bio Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aeglea Bio's history and understand the potential risks before investing.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |